Edition:
United States

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

36.24USD
1:48pm EST
Change (% chg)

$-0.03 (-0.07%)
Prev Close
$36.26
Open
$36.06
Day's High
$36.49
Day's Low
$35.96
Volume
2,446,177
Avg. Vol
6,141,389
52-wk High
$39.43
52-wk Low
$31.67

Chart for

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.91
Market Cap(Mil.): $216,135.30
Shares Outstanding(Mil.): 5,960.71
Dividend: 0.34
Yield (%): 3.75

Financials

  Industry Sector
P/E (TTM): -- 32.45 17.28
EPS (TTM): -- -- --
ROI: -- 14.04 35.61
ROE: -- 15.50 17.17

BRIEF-Spark Therapeutics Enters Into A Spk-9001 Manufacture And Supply Agreement With Pfizer

* SPARK THERAPEUTICS INC - ON FEB 16, CO ENTERED INTO A SPK-9001 MANUFACTURE AND SUPPLY AGREEMENT WITH PFIZER - SEC FILING

8:22am EST

UPDATE 1-UK shares retreat as Reckitt disappoint

LONDON, Feb 19 British shares lost some ground on Monday as weak results from Reckitt Benckiser underlined the murky growth outlook for big consumer goods makers and banking holidays in the U.S. and China slowed European markets.

Feb 19 2018

BRIEF-Reckitt CEO bullish on consumer health, no comment on Pfizer

* RECKITT BENCKISER CEO SAYS NO COMMENT ON PFIZER CONSUMER HEALTH AUCTION

Feb 19 2018

Shares of Apricus tank after FDA declines to OK erectile dysfunction cream

The U.S. Food and Drug Administration on Friday declined to approve Apricus Biosciences Inc's Vitaros, a cream to treat erectile dysfunction, for the second time in a decade, sending the company's shares down more than 70 percent before the opening bell.

Feb 16 2018

UPDATE 2-Shares of Apricus tank after FDA declines to OK erectile dysfunction cream

* Co set to lose 76 pct of market value (Adds background on drug, analyst comment, updates share price)

Feb 16 2018

AbbVie to buy back $10 billion of shares, raises dividend

AbbVie Inc said on Thursday its board had approved a $10 billion stock repurchase program, and the drugmaker also increased its quarterly dividend, as it reaped the benefits of U.S. tax law changes.

Feb 15 2018

UPDATE 1-AbbVie to buy back $10 billion of shares, raises dividend

Feb 15 AbbVie Inc said on Thursday its board had approved a $10 billion stock repurchase program, and the drugmaker also increased its quarterly dividend, as it reaped the benefits of U.S. tax law changes.

Feb 15 2018

Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

FRANKFURT Merck KGaA and Pfizer received a setback on Thursday for their drug Bavencio, which is a late starter in the rapidly evolving field of cancer immunotherapies.

Feb 15 2018

UPDATE 1-Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

* Merck still sees potential against lung cancer for Bavencio (Adds trial details, background on immunotherapies)

Feb 15 2018

Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

FRANKFURT, Feb 15 Merck KGaA and Pfizer's cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.

Feb 15 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $131.29 -1.86
Novartis AG (NOVN.S) CHF80.46 +0.78
Merck & Co., Inc. (MRK.N) $55.04 -1.25
Roche Holding Ltd. (ROG.S) CHF223.90 +0.75
Roche Holding Ltd. (RO.S) CHF226.80 +0.80
Abbott Laboratories (ABT.N) $59.20 -0.97
Bayer AG (BAYGn.DE) €98.93 +1.15
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €64.55 +0.25
AstraZeneca plc (AZN.L) 4,722.00 +9.50

Earnings vs. Estimates